How healthcare will remain the most important industry in the world for decades to come - and the UK can be a big player

31 May 2016
2019_biotech_test_vial_discovery_big

In our weekly expert view piece, British entrepreneur Jim Mellon, predicts future trends and patterns in the biopharmaceutical space.

Recently I spoke at BioTrinity 2016 in London, an industry conference for health care professionals, and probably the most important in the UK.

Prior to me speaking, George Freeman, the UK’s Minister for Life Sciences, made a politician's lengthy speech about how the government was committed to biotech, was “investing” in it, and was an advocate of its fundamental importance to the UK economy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology